期刊
JOURNAL OF CLINICAL PSYCHIATRY
卷 72, 期 9, 页码 1263-1269出版社
PHYSICIANS POSTGRADUATE PRESS
DOI: 10.4088/JCP.11m07003
关键词
-
资金
- National Alliance for Research on Schizophrenia and Depression (NARSAD)
- National Institutes of Health/the National Institute of Mental Health (NIMH)
- National Institute on Drug Abuse
- National Institute of Neurological Disorders and Stroke
- National Institute on Aging
- NARSAD
- Stanley Foundation
- Cyberonics
- Neuronetics (past)
- St Jude Medical (Advanced Neuromodulation Systems)
- Magstim
- Brainsway
- Otsuka
- Neuronetics
- Sunovion
- AstraZeneca
- NIMH
- Eli Lilly
- Forest
- GlaxoSmithKline
- Somerset
- American Academy of Child and Adolescent Psychiatry/Eli Lilly
- Department of Psychiatry and Psychology, Mayo Clinic
- Stanley Medical Research Institute Center
Objective: Depression is often a serious and debilitating illness in adolescents. Unfortunately, a significant number of adolescents do not respond to antidepressant medications or psychotherapy. Repetitive transcranial magnetic stimulation (rTMS) is a novel treatment intervention shown to benefit depression in adults, This study considered rTMS as an adjunctive treatment in adolescents with major depressive disorder. Method: This prospective, open, multicenter trial of active adjunctive rTMS was conducted with 8 adolescents with DSM-IV-TR major depressive disorder (MDD) that had not responded sufficiently to 2 adequate antidepressant medication trials. All subjects were maintained on a stable dose of a selective serotonin reuptake inhibitor during the trial. Thirty daily rTMS treatments were given 5 days per week over 6 to 8 weeks, rTMS was applied to the left dorsolateral prefrontal cortex (120% of motor threshold; 10 Hz; 4-second trains; 26-second intertrain interval; 75 trains) for a total of 3,000 stimulations per treatment session. Results: Seven of 8 adolescents completed all 30 treatments. rTMS was well tolerated, and no significant safety issues were identified. Suicidal ideation was present at baseline in 3 of the adolescents, and it improved during treatment. The primary outcome measure was the Children's Depression Rating Scale-Revised (CDRS-R); results improved significantly from baseline (mean [SD]) (65.9 [6.6]) to treatment 10(50.9 [12]), P <.02. The CDRS-R scores continued to improve through the rTMS treatment series at treatment 20 (40.1 [14]), P <.01; treatment 30 (32.6 [7.3]), P <.0001; and at 6-month follow-up (32.7 [3.8]), P <.0001. Conclusions: This prospective open trial suggests that rTMS is a safe, feasible, and potentially effective adjunctive therapy for treatment-resistant MDD in adolescents. Trial Registration: clinicaltrials.gov Identifier: NCT00587639 J Clin Psychiatry 2011;72(9):1263-1269 (C) Copyright 2011 Physicians Postgraduate Press, Inc.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据